Sub-category 8.1 - Cytotoxic drugs
Abiraterone for the treatment of castration-resistant prostate cancer
Evaluation report
Feb 11
Azacitidine for the management of myelodysplastic syndromes
May 09
Bendamustine for rituximab-refractory non-hodgkin’s lymphoma
Bevacizumab in metastatic breast cancer
Sep 07
Bortezomib second-line in multiple myeloma (N)
Mar 06
Cabazitaxel for the treatment of metastatic hormone-refractory prostate cancer
Dasatinib in the management of acutelymphoblastic leukaemia in adults
Aug 08
Docetaxel or paclitaxel in early stage breast cancer (N)
Erlotinib in non-small cell lung cancer
Herceptin B-31_N9831
Rapid Appraisal
09
Nov 05
Herceptin HERA
08
Ibritumomab as consolidation therapy after remission induction in previously untreated follicular lymphoma
Myocet in the management of metastatic breast cancer
Oct 08
Nanoparticle albumin-bound paclitaxel in the management of metastatic breast cancer
May 10
Panitumumab in the management of metastatic colorectal cancer
Jun 09
Pemetrexed in malignant pleural mesothelioma (N)
Sorafenib for the treatment of locally advanced or metastatic medullary thyroid cancer
Sunitinib for the treatment of Pancreatic Neuroendocrine Tumours (PNETs)
Mar 11
Vandetanib in locally advanced or metastatic medullary thyroid cancer
Home | About us | Management | Publications | Education | Services | Links | Contact us | Search
RSS Feed
Site last updated 03/02/2012
